Yohei Ohno provides his takeaways from the results of the SURVIV trial, which were presented by Dimytri Siqueira during the ACC.26 in New Orleans.

Ref 02P - Updated June 2024

Consult this Twitter case from Ricardo Sanz: an 80-year-old man presenting with inferior STEMI, primary PCI being complicated by the presence of a giant coronary aneurysm in the RCA that hindered the advancement of wires and material towards a small and hidden entry point. Creative off-label...

Launched in December 2023 by our community through the ‘We CARE Alliance’ and co-funded by the EU4Health work programme, the mission of the RESIL-Card project is to ensure that essential healthcare services for people with cardiovascular (CV) diseases are maintained during crises. Specifically, the project aims to...

Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Updated - August 22nd, 2023

Chiara De Biase provides her take on the FAST III Trial presented by Joost Daemen at ACC.26 in New Orleans. She reviews the comparison between vFFR and FFR, highlighting key findings and their impact on revascularisation strategies.

Paris, France. 21 May 2021.  Since 1989, EuroPCR has constantly pioneered innovative educational tools and formats to help the interventional cardiovascular community effectively share their knowledge, skills and practice. Rising up to the challenge of the pandemic, the 31st annual edition was fundamentally rethought, reshaped and...

Paris, May 2022: A festive EuroPCR 2022 – the World Leading Course in interventional cardiovascular medicine – took place again in person, after a hiatus of 2 years caused by the COVID19 pandemic. The new blended EuroPCR format attracted 11,000 participants in person and online with...

Transcatheter interventions have rapidly reshaped the management of tricuspid valve disease, with landmark trials establishing feasibility and early clinical benefit.

Beyond these pivotal studies, a series of less visible but highly informative papers addressed mechanisms, complications, patient phenotypes, and unintended consequences of intervention.

This curated selection highlights ten impactful tricuspid...

Aaysha Cader provides her take on the Short-CUT trial presented by Suzanne J. Baron at TCT 2025, in San Francisco.

Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.

Daniele Giacoppo reports and provides his perspective on the main results of the IVUS-CHIP trial, presented by Roberto Diletti from the Erasmus University Medical Center, Rotterdam, the Netherlands, during a Late-Breaking Trials session at the ACC.26 in New Orleans, and simultaneously published in the New England Journal of...

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...